当前位置: 首页 >> 检索结果
241. Incidental Coronary Artery Calcium: Opportunistic Screening of Previous Nongated Chest Computed Tomography Scans to Improve Statin Rates (NOTIFY-1 Project).
作者: Alexander T Sandhu.;Fatima Rodriguez.;Summer Ngo.;Bhavik N Patel.;Domenico Mastrodicasa.;David Eng.;Nishith Khandwala.;Sujana Balla.;Doug Sousa.;David J Maron.
来源: Circulation. 2023年147卷9期703-714页
Coronary artery calcium (CAC) can be identified on nongated chest computed tomography (CT) scans, but this finding is not consistently incorporated into care. A deep learning algorithm enables opportunistic CAC screening of nongated chest CT scans. Our objective was to evaluate the effect of notifying clinicians and patients of incidental CAC on statin initiation.
242. Randomized Controlled Trial of a Smartphone-Based Intervention to Enhance 6-Minute Walk Distance During Breast Cancer Treatment: The SMART-BREAST Trial.
作者: Alexandra C Murphy.;Omar Farouque.;Anoop N Koshy.;Belinda Yeo.;Ron Dick.;Voltaire Nadurata.;Laura Roccisano.;Christopher Reid.;Matias B Yudi.
来源: Circulation. 2023年147卷7期614-616页 243. Aspirin Versus Clopidogrel for Long-Term Maintenance Monotherapy After Percutaneous Coronary Intervention: The HOST-EXAM Extended Study.
作者: Jeehoon Kang.;Kyung Woo Park.;Huijin Lee.;Doyeon Hwang.;Han-Mo Yang.;Seung-Woon Rha.;Jang-Whan Bae.;Nam Ho Lee.;Seung-Ho Hur.;Jung-Kyu Han.;Eun-Seok Shin.;Bon-Kwon Koo.;Hyo-Soo Kim.
来源: Circulation. 2023年147卷2期108-117页
Long-term outcomes of antiplatelet monotherapy in patients who receive percutaneous coronary intervention are unknown. The HOST-EXAM (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Extended Antiplatelet Monotherapy) Extended study reports the posttrial follow-up results of the original HOST-EXAM trial.
244. Exercise for the Prevention of Anthracycline-Induced Functional Disability and Cardiac Dysfunction: The BREXIT Study.
作者: Stephen J Foulkes.;Erin J Howden.;Mark J Haykowsky.;Yoland Antill.;Agus Salim.;Sophie S Nightingale.;Sherene Loi.;Piet Claus.;Kristel Janssens.;Amy M Mitchell.;Leah Wright.;Ben T Costello.;Anniina Lindqvist.;Lauren Burnham.;Imogen Wallace.;Robin M Daly.;Steve F Fraser.;André La Gerche.
来源: Circulation. 2023年147卷7期532-545页
Breast cancer survivors treated with anthracycline-based chemotherapy (AC) have increased risk of functional limitation and cardiac dysfunction. We conducted a 12-month randomized controlled trial in 104 patients with early-stage breast cancer scheduled for AC to determine whether 12 months of exercise training (ExT) could attenuate functional disability (primary end point), improve cardiorespiratory fitness (VO2peak), and prevent cardiac dysfunction.
245. Survival After Invasive or Conservative Management of Stable Coronary Disease.
作者: Judith S Hochman.;Rebecca Anthopolos.;Harmony R Reynolds.;Sripal Bangalore.;Yifan Xu.;Sean M O'Brien.;Stavroula Mavromichalis.;Michelle Chang.;Aira Contreras.;Yves Rosenberg.;Ruth Kirby.;Balram Bhargava.;Roxy Senior.;Ann Banfield.;Shaun G Goodman.;Renato D Lopes.;Radosław Pracoń.;José López-Sendón.;Aldo Pietro Maggioni.;Jonathan D Newman.;Jeffrey S Berger.;Mandeep S Sidhu.;Harvey D White.;Andrea B Troxel.;Robert A Harrington.;William E Boden.;Gregg W Stone.;Daniel B Mark.;John A Spertus.;David J Maron.; .
来源: Circulation. 2023年147卷1期8-19页
The ISCHEMIA trial (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches) compared an initial invasive versus an initial conservative management strategy for patients with chronic coronary disease and moderate or severe ischemia, with no major difference in most outcomes during a median of 3.2 years. Extended follow-up for mortality is ongoing.
246. A Randomized Controlled Trial Comparing Apixaban With the Vitamin K Antagonist Phenprocoumon in Patients on Chronic Hemodialysis: The AXADIA-AFNET 8 Study.
作者: Holger Reinecke.;Christiane Engelbertz.;Rupert Bauersachs.;Günter Breithardt.;Hans-Herbert Echterhoff.;Joachim Gerß.;Karl Georg Haeusler.;Bernd Hewing.;Joachim Hoyer.;Sabine Juergensmeyer.;Thomas Klingenheben.;Guido Knapp.;Lars Christian Rump.;Hans Schmidt-Guertler.;Christoph Wanner.;Paulus Kirchhof.;Dennis Goerlich.
来源: Circulation. 2023年147卷4期296-309页
Non-vitamin K oral anticoagulants have become the standard therapy for preventing stroke and ischemic thromboembolism in most patients with atrial fibrillation (AF). The effectiveness and safety of non-vitamin K oral anticoagulants in patients on hemodialysis is not well known.
247. Apixaban for Patients With Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial.
作者: Sean D Pokorney.;Glenn M Chertow.;Hussein R Al-Khalidi.;Dianne Gallup.;Pat Dignacco.;Kurt Mussina.;Nisha Bansal.;Crystal A Gadegbeku.;David A Garcia.;Samira Garonzik.;Renato D Lopes.;Kenneth W Mahaffey.;Kelly Matsuda.;John P Middleton.;Jennifer A Rymer.;George H Sands.;Ravi Thadhani.;Kevin L Thomas.;Jeffrey B Washam.;Wolfgang C Winkelmayer.;Christopher B Granger.; .
来源: Circulation. 2022年146卷23期1735-1745页
There are no randomized data evaluating the safety or efficacy of apixaban for stroke prevention in patients with end-stage kidney disease on hemodialysis and with atrial fibrillation (AF).
248. Indobufen or Aspirin on Top of Clopidogrel After Coronary Drug-Eluting Stent Implantation (OPTION): A Randomized, Open-Label, End Point-Blinded, Noninferiority Trial.
作者: Hongyi Wu.;Lili Xu.;Xin Zhao.;Huanyi Zhang.;Kang Cheng.;Xiaoyan Wang.;Manhua Chen.;Guangping Li.;Jiangnan Huang.;Jun Lan.;Guanghe Wei.;Chi Zhang.;Yinman Wang.;Juying Qian.;Junbo Ge.; .
来源: Circulation. 2023年147卷3期212-222页
Dual antiplatelet therapy (DAPT) with aspirin as a background therapy has become the standard care after percutaneous coronary intervention. However, some adverse noncardiac effects limited the use of aspirin in clinical practice. Thus, evaluation of pharmacological alternatives to aspirin is attractive. Previous data indicated that indobufen could lessen the unwanted side effects of aspirin while retaining the antithrombotic efficacy, but its combination with a P2Y12 inhibitor still lacks randomized clinical trial evidence.
249. Myosin Inhibition and Left Ventricular Diastolic Function in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Insights From the VALOR-HCM Study.
作者: Paul C Cremer.;Jeffrey B Geske.;Anjali Owens.;Wael A Jaber.;Serge C Harb.;Sara Saberi.;Andrew Wang.;Mark Sherrid.;Srihari S Naidu.;Hartzell Schaff.;Nicholas G Smedira.;Qiuqing Wang.;Kathy Wolski.;Kathy L Lampl.;Amy J Sehnert.;Steven E Nissen.;Milind Y Desai.
来源: Circ Cardiovasc Imaging. 2022年15卷12期e014986页
In the randomized phase 3 VALOR-HCM study (A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Who Are Eligible for Septal Reduction Therapy) of patients with obstructive hypertrophic cardiomyopathy, mavacamten reduced the need for septal reduction therapy. Because mavacamten improves ventricular compliance, this sub-study examined the effects of treatment with this cardiac myosin inhibitor on diastolic function.
250. Dose-Blinded Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Outcomes Through 32 Weeks.
作者: Milind Y Desai.;Anjali Owens.;Jeffrey B Geske.;Kathy Wolski.;Sara Saberi.;Andrew Wang.;Mark Sherrid.;Paul C Cremer.;Srihari S Naidu.;Nicholas G Smedira.;Hartzell Schaff.;Ellen McErlean.;Christina Sewell.;Aarthi Balasubramanyam.;Kathy Lampl.;Amy J Sehnert.;Steven E Nissen.
来源: Circulation. 2023年147卷11期850-863页
Septal reduction therapy (SRT) in patients with intractable symptoms from obstructive hypertrophic cardiomyopathy (oHCM) is associated with variable morbidity and mortality. The VALOR-HCM trial (A Study to Evaluate Mavacamten in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy Who Are Eligible for Septal Reduction Therapy) examined the effect of mavacamten on the need for SRT through week 32 in oHCM.
251. Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial.
作者: Kim A Connelly.;C David Mazer.;Pankaj Puar.;Hwee Teoh.;Chao-Hung Wang.;Tamique Mason.;Farhad Akhavein.;Ching-Wen Chang.;Min-Hui Liu.;Ning-I Yang.;Wei-Siang Chen.;Yu-Hsiang Juan.;Erika Opingari.;Yaseen Salyani.;William Barbour.;Aryan Pasricha.;Shamon Ahmed.;Andrew Kosmopoulos.;Raj Verma.;Michael Moroney.;Ehab Bakbak.;Aishwarya Krishnaraj.;Deepak L Bhatt.;Javed Butler.;Mikhail N Kosiborod.;Carolyn S P Lam.;David A Hess.;Otavio Rizzi Coelho-Filho.;Myriam Lafreniere-Roula.;Kevin E Thorpe.;Adrian Quan.;Lawrence A Leiter.;Andrew T Yan.;Subodh Verma.
来源: Circulation. 2023年147卷4期284-295页
Sodium-glucose cotransporter 2 inhibitors have been demonstrated to promote reverse cardiac remodeling in people with diabetes or heart failure. Although it has been theorized that sodium-glucose cotransporter 2 inhibitors might afford similar benefits in people without diabetes or prevalent heart failure, this has not been evaluated. We sought to determine whether sodium-glucose cotransporter 2 inhibition with empagliflozin leads to a decrease in left ventricular (LV) mass in people without type 2 diabetes or significant heart failure.
252. Decongestion With Acetazolamide in Acute Decompensated Heart Failure Across the Spectrum of Left Ventricular Ejection Fraction: A Prespecified Analysis From the ADVOR Trial.
作者: Pieter Martens.;Jeroen Dauw.;Frederik H Verbrugge.;Petra Nijst.;Evelyne Meekers.;Silvio Nunes Augusto.;Jozine M Ter Maaten.;Kevin Damman.;Alexandre Mebazaa.;Gerasimos Filippatos.;Frank Ruschitzka.;W H Wilson Tang.;Matthias Dupont.;Wilfried Mullens.
来源: Circulation. 2023年147卷3期201-211页
Acetazolamide inhibits proximal tubular sodium reabsorption and improved decongestion in the ADVOR (Acetazolamide in Decompensated Heart Failure with Volume Overload) trial. It remains unclear whether the decongestive effects of acetazolamide differ across the spectrum of left ventricular ejection fraction (LVEF).
253. Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock: Results of the ECMO-CS Randomized Clinical Trial.
作者: Petr Ostadal.;Richard Rokyta.;Jiri Karasek.;Andreas Kruger.;Dagmar Vondrakova.;Marek Janotka.;Jan Naar.;Jana Smalcova.;Marketa Hubatova.;Milan Hromadka.;Stefan Volovar.;Miroslava Seyfrydova.;Jiri Jarkovsky.;Michal Svoboda.;Ales Linhart.;Jan Belohlavek.; .
来源: Circulation. 2023年147卷6期454-464页
Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is increasingly being used for circulatory support in patients with cardiogenic shock, although the evidence supporting its use in this context remains insufficient. The ECMO-CS trial (Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock) aimed to compare immediate implementation of VA-ECMO versus an initially conservative therapy (allowing downstream use of VA-ECMO) in patients with rapidly deteriorating or severe cardiogenic shock.
254. Impact of Patient-Reported Outcome Measurement in Heart Failure Clinic on Clinician Health Status Assessment and Patient Experience: A Substudy of the PRO-HF Trial.
作者: Alexander T Sandhu.;Jimmy Zheng.;Neil M Kalwani.;Anshal Gupta.;Jamie Calma.;Megan Skye.;Roy Lan.;Brian Yu.;John A Spertus.;Paul A Heidenreich.
来源: Circ Heart Fail. 2023年16卷2期e010280页
Clinicians typically estimate heart failure health status using the New York Heart Association Class, which is often discordant with patient-reported health status. It is unknown whether collecting patient-reported health status improves the accuracy of clinician assessments.
255. The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI Trial.
作者: Roxana Mehran.;Philippe Gabriel Steg.;Marc A Pfeffer.;Karola Jering.;Brian Claggett.;Eldrin F Lewis.;Christopher Granger.;Lars Køber.;Aldo Maggioni.;Douglas L Mann.;John J V McMurray.;Jean-Lucien Rouleau.;Scott D Solomon.;Gregory Ducrocq.;Otavio Berwanger.;Carmine G De Pasquale.;Ulf Landmesser.;Mark Petrie.;David Sim Kheng Leng.;Peter van der Meer.;Martin Lefkowitz.;Yinong Zhou.;Eugene Braunwald.
来源: Circulation. 2022年146卷23期1749-1757页
In patients who survive an acute myocardial infarction (AMI), angiotensin-converting enzyme inhibitors decrease the risk of subsequent major cardiovascular events. Whether angiotensin-receptor blockade and neprilysin inhibition with sacubitril/valsartan reduce major coronary events more effectively than angiotensin-converting enzyme inhibitors in high-risk patients with recent AMI remains unknown. We aimed to compare the effects of sacubitril/valsartan on coronary outcomes in patients with AMI.
256. In-Hospital Virtual Peer-to-Peer Consultation to Increase Guideline-Directed Medical Therapy for Heart Failure: A Pilot Randomized Trial.
作者: Vishal N Rao.;Anand Shah.;Jaime McDermott.;Stephanie G Barnes.;Evan M Murray.;Michelle D Kelsey.;Stephen J Greene.;Marat Fudim.;Adam D DeVore.;Chetan B Patel.;Michael A Blazing.;Cara O'Brien.;Robert J Mentz.
来源: Circ Heart Fail. 2023年16卷2期e010158页
Guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF) improves clinical outcomes and quality of life. Optimizing GDMT in the hospital is associated with greater long-term use in HFrEF. This study aimed to describe the efficacy of a multidisciplinary virtual HF intervention on GDMT optimization among patients with HFrEF admitted for any cause.
257. Comparing New York Heart Association Class and Patient-Reported Outcomes Among Patients Hospitalized for Heart Failure.
作者: Michael F Cosiano.;Andrew Vista.;Jie-Lena Sun.;Brooke Alhanti.;Josephine Harrington.;Javed Butler.;Randall C Starling.;Robert J Mentz.;Stephen J Greene.
来源: Circ Heart Fail. 2023年16卷1期e010107页
Alignment between clinician-reported New York Heart Association (NYHA) class compared and patient-reported outcomes among patients hospitalized for heart failure is unclear.
258. A Randomized, Controlled Trial of Resistance Training Added to Caloric Restriction Plus Aerobic Exercise Training in Obese Heart Failure With Preserved Ejection Fraction.
作者: Peter H Brubaker.;Barbara J Nicklas.;Denise K Houston.;W Gregory Hundley.;Haiying Chen.;Anthony J A Molina.;W Mary Lyles.;Benjamin Nelson.;Bharathi Upadhya.;Russell Newland.;Dalane W Kitzman.
来源: Circ Heart Fail. 2023年16卷2期e010161页
We have shown that combined caloric restriction (CR) and aerobic exercise training (AT) improve peak exercise O2 consumption (VO2peak), and quality-of-life in older patients with obese heart failure with preserved ejection fraction. However, ≈35% of weight lost during CR+AT was skeletal muscle mass. We examined whether addition of resistance training (RT) to CR+AT would reduce skeletal muscle loss and further improve outcomes.
259. Long-Term Mortality Follow-Up of Radial Artery Versus Saphenous Vein in Coronary Artery Bypass Grafting: A Multicenter, Randomized Trial.
作者: Steven Goldman.;Madeline McCarren.;Gulshan K Sethi.;William Holman.;Faisal G Bakaeen.;Todd H Wagner.;Yajie Wang.;Mei-Chung Shih.;Robert Edson.; .
来源: Circulation. 2022年146卷17期1323-1325页 260. Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome and High Bleeding Risk.
作者: Shqipdona Lahu.;Antonia Presch.;Gjin Ndrepepa.;Maurizio Menichelli.;Christian Valina.;Rayyan Hemetsberger.;Bernhard Witzenbichler.;Isabell Bernlochner.;Michael Joner.;Erion Xhepa.;Alexander Hapfelmeier.;Sebastian Kufner.;Nonglag Rifatov.;Hendrik B Sager.;Katharina Mayer.;Thorsten Kessler.;Karl-Ludwig Laugwitz.;Gert Richardt.;Heribert Schunkert.;Franz-Josef Neumann.;Dirk Sibbing.;Dominick J Angiolillo.;Adnan Kastrati.;Salvatore Cassese.
来源: Circ Cardiovasc Interv. 2022年15卷10期e012204页
The relative efficacy and safety of more potent P2Y12 inhibitors in patients with acute coronary syndrome and high bleeding risk (HBR) undergoing percutaneous coronary intervention remains unclear. We aimed to study the treatment effect of ticagrelor and prasugrel in percutaneous coronary intervention patients presenting with acute coronary syndrome and HBR.
|